First company to launch a RT PCR detection kit COVID-19
GENOMICA became the first Spanish company to launch a RT PCR COVID-19 detection kit with CE marking on March 6, 2020. Since January 12, 2020, when the coronavirus sequence was published in China, GENOMICA started a race against time to be able to produce its own diagnostic kit and offer immediate responses to the pandemic. GENOMICA’s commitment is always to be at the service of society and is being reflected once again since the origin of the pandemic.
qCOVID-19 Respiratory Combo* is designed as a real-time multiplex RT-PCR kit designed to differentially detect SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV A/B). This kit has been validated with nasopharyngeal samples from patients with respiratory infections, with a diagnostic sensitivity and specificity close to 100%. In addition, for the detection of SARS-CoV-2, , the kit has been validated with saliva samples.
This PCR test, a reference method for virus detection, allows differentiation of the SARS-CoV-2 virus, the cause of the current COVID-19 pandemic, from other viruses due to the similarity of the symptoms manifested by these common respiratory diseases: influenza A, influenza B and infections caused by RSV. In this way, a rapid and accurate diagnosis can be made, enabling physicians to classify and determine the most appropriate treatment and isolation measures for each patient.
The kit is based on the principle of Taqman probes and the retrotranscription reaction and amplification of the cDNA is carried out in one step allowing 48 samples to be analyzed in a single analysis in 90 min.
* * Our kits are for sale and use only in hospitals and professional molecular biology laboratories. Instrumentation and qualified personnel are required. Not available for sale to the public or pharmacies. If you meet these requirements, please contact our sales team by e-mail: email@example.com.